Trial site
New Haven
New Haven, Connecticut 06511, United StatesNot linked to an institution yet
- 15running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 27 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Recruiting7 trials
- Completed4 trials
- Lead sponsor
- GlaxoSmithKline12 trials
- ViiV Healthcare5 trials
- Tesaro, Inc.2 trials
Running trials
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Contact: Onyema Ogbuagu (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
NCT07224672· Phase 2· GlaxoSmithKline· Source
Contact: Sabrina Browning (principal investigator)
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· Phase 2· ViiV Healthcare· Source
Contact: Onyema Ogbuagu (principal investigator)
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880· Phase 1/2· GlaxoSmithKline· Source
Contact: Daniel Petrylak (principal investigator)
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867· Phase 2· GlaxoSmithKline· Source
Contact: Amer Zeidan (principal investigator)
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· Phase 3· ViiV Healthcare· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Barbara Burtness (principal investigator)
Active, not recruiting
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386· Phase 4· GlaxoSmithKline· Source
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471· Phase 2· ViiV Healthcare· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Contact: Jeremy Kortmansky (principal investigator)
Active, not recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· Phase 3· ViiV Healthcare· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error